CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null DiseaseNing Zhao, Michael J. Evans|Clinical Cancer Research|2022Cited by 30
Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 SignalingJunnian Wei, Michael J. Evans|Molecular & Cellular Proteomics|2019Cited by 14
Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder CancerShalini Chopra, Michael J. Evans|Clinical Cancer Research|2023Cited by 11
674 Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving ¹ <sup>7</sup> <sup>7</sup> Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune responseAnusha Muralidhar, Lawrence Fong, Zenghua Fan et al.|Regular and Young Investigator Award Abstracts|2025Cited by 0